Glibenclamide, a blocker of K+ATP channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasis

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 12, 2006, Pages 4214-4216

  Serrano Martín, Xenón ^a   Payares, Gilberto ^a   Mendoza León, Alexis ^a  

^a FACULTAD DE CIENCIAS   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEISHMANIAL AGENT; GLIBENCLAMIDE; MEGLUMINE ANTIMONATE; POTASSIUM CHANNEL BLOCKING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; GROWTH INHIBITION; LEISHMANIA; LEISHMANIA MEXICANA; MOUSE; NONHUMAN; POTASSIUM TRANSPORT; PRIORITY JOURNAL; SKIN LEISHMANIASIS;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTIPROTOZOAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; GLYBURIDE; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; POTASSIUM CHANNEL BLOCKERS;

EID: 33845245831     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00617-06     Document Type: Article

References (16)

1. Adinolfi, L. E., P. F. Bonventre, M. V. Pas, and D. A. Eppstein. 1985. Synergistic effect of glucantime and a liposome-encapsulated muramyl dipeptide analog in therapy of experimental visceral leishmaniasis. Infect. Immun. 48:409-416.
2. Ashcroft, F. M. 2005. ATP-sensitive potassium channelopathies: focus on insulin secretion. J. Clin. Investig. 115:2047-2057.
3. Berman, D., N. Edwards, M. King, and M. Grogl. 1989. Biochemistry of Pentostam resistant Leishmania. Am. J. Trop. Med. Hyg. 40:159-164.
4. Croft, S. L., and G. H. Coombs. 2003. Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 19:502-508.
5. Croft, S. L., M. P., Barrett, and J. U. Urbina. 2005. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol. 21:508-512.
6. Croft, S. L., S. Sundar, and A. Fairlamb. 2006. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 19:111-126.
7. Golstein, P. E., A. Boom, J. van Geffel, P. Jacobs, B. Masereel, and R. Beauwens. 1999. P-glycoprotein inhibition by glibenclamide and related compounds. Pflügers Arch. Eur. J. Physiol. 437:652-660.
8. Gourbal, B., N. Sonuc, H. Bhattacharjee, D. Legare, S. Sundar, M. Oullette, B. Rosen, and R. Mukhopadhyay. 2004. Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J. Biol. Chem. 279:31010-31017.
9. 50 in studies of drug resistance in malaria parasites. Acta Trop. 55:257-261.
10. Leandro, C., and L. Campino. 2003. Leishmaniasis: efflux pumps and chemoresistance. Int. J. Antimicrob. Agents 22:352-357.
11. Légaré, D., S. Cayer, A. Singh, R. Dave, B. Papadopoulou, and M. Oullette. 2001. ABC proteins in Leishmania. J. Bioenerg. Biomembr. 33:469-474.
12. Oullette, M., J. Drummelsmith, and B. Papadopoulou. 2004. Leishmaniasis: drug in the clinic, resistance and new developments. Drug Resist. Updates 7:257-266.
13. Ponte-Sucre, A., Y. Campos, M. Fernandez, H. Moll, and A. Mendoza-León. 1998. Leishmania sp.: growth and survival are impaired by ion channel blockers. Exp. Parasitol. 88:11-19.
14. Ponte-Sucre, A., A. Mendoza-León, and H. Moll. 2001. Experimental leishmaniasis: synergistic effect of ion channel blockers and interferon-γ on the clearance of Leishmania major by macrophages. Parasitol. Res. 87:27-31.
15. Rosen, B. 2002. Biochemistry of arsenic detoxification. FEBS Lett. 529:86-92.
16. Sundar, S., K. Rosenkaimer, M. K. Makharia, A. K. Goyal, A. K. Mandal, A. Voss, P. Hilgard, and H. W. Murray. 1998. Trial of oral miltefosine for visceral leishmaniasis. Lancet 352:1821-1823.